Vorasidenib was first approved in 2024 for the treatment of Grade 2 gliomas with isocitrate dehydrogenase 1 and 2 mutations and is now approved in over 40 countries, including Japan. During early development, vorasidenib pharmacokinetics (PK) was estimated in populations without Japanese participants. In 2019, this Phase 1 single ascending (two levels) dose study (NCT04145128)… →

CONCLUSION: In a large, real-world study designed to emulate a clinical trial, GLP-1 RAs were linked to increased psoriasis and decreased autoimmune blistering diseases compared with DPP-4is over up to 4 years’ follow-up. These results provide a dermatologic safety context to guide incretin therapy selection and highlight the importance of ongoing skin monitoring. →

Purpose: This study compares the accuracy of dental students in diagnosing different breathing sounds using traditional versus artificial intelligence-assisted precordial stethoscopes (AIPS). Methods: The study involved 45 3rd- and 4th-year dental students who completed a pre-test to assess their baseline knowledge of breathing sounds. After watching a learning video, participants were randomized into 3 groups:… →

CONCLUSION: SOX therapy as consolidation chemotherapy after CRT was safe and well tolerated as part of the TNT for lower rectal cancer. To our knowledge, this is the first study to report the use of SOX in TNT. Further trials are warranted to evaluate the efficacy of SOX as consolidation therapy after CRT in larger… →

CONCLUSION: Findings suggest that long duration exercise of a standardized moderate intensity may not be effective to induce EIH in trained male cyclists, while also no hyperalgesia is observed. These results are not different between loaded and unloaded body parts. →

African American faith institutions can play a key role in increasing HIV education and testing in communities disproportionately burdened by HIV. This focus group study explored church participant perspectives of a religiously tailored HIV education and testing intervention implemented through a clustered, randomized controlled trial with 14 African American churches in Kansas City. Focus group… →

CONCLUSIONS: CH was frequent in patients with AA and its prevalence appeared to be higher at posttherapy timepoints than at diagnosis. CH in AA may reflect the survival and expansion of selected residual hematopoietic stem/progenitor cells associated with immune-mediated damage. (Funded by Cancer Research UK, Bloodwise UK, and Novartis AG; ClinicalTrials.gov number, NCT02099747; EudraCT number,… →